Replies to post #243954 on Biotech Values

[swampboots]

Re: the :experimental Alzheimer’s drug. Notable to me:
the primary endpoint relies on qualified professionals" to essentially measure performance in six areas: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care.

In my opinion it is the secondary endpoint which deserves repeated confirmation: PROFILE OF AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA) ( 5% observed drop in plague load {17% to 12%}).
The benefit of approval to me rests on society determining the value of having a faithful" tool to meet the dreadful outcomes
of having nothing else to soften the onslaught of the consequences to all parties affected by Alzheimer's if the safety profiles are adequately met.
However this highly valuable palliative to reduce some of the depressing associative consequences of a diagnosis of Alzheimer's must
balance the ultimate dollar cost to the financial health of our health care system.

[WorstLuck]

I don't think anyone was expecting earth-shattering results. They were well within the range of reasonable expectation for the trial design and prior trial results, correct?

The potential value of the treatment can be and will be argued, lol, but not by me.